Clinical Trial: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomized, Placebo-controlled, Double Blind Phase II/III Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With

Brief Summary: The purpose of this single-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.

Detailed Summary:
Sponsor: Pharming Technologies B.V.

Current Primary Outcome: Primary outcomes: Relief of angioedema symptoms

Original Primary Outcome: Relief of angioedema symptoms

Current Secondary Outcome: Secondary outcomes: Safety and tolerability; pharmacokinetics/pharmacodynamics

Original Secondary Outcome: Safety and tolerability; pharmacokinetics/pharmacodynamics

Information By: Pharming Technologies B.V.

Dates:
Date Received: September 20, 2005
Date Started: July 2005
Date Completion:
Last Updated: April 24, 2013
Last Verified: April 2013